Medical imaging company Sectra (STO:SECT B) revealed on Friday the launch of a digital pathology contract, valued at EUR2.3m, with the Region of Southern Denmark.
The Region of Southern Denmark is reportedly the first Danish healthcare region to digitise pathology in full scale, added the company.
Through the company's digital pathology solution, the resource utilisation and sub-specialisation will be optimised at the four geographically dispersed hospitals in Southern Denmark. All patients, regardless of location, will get equal access to healthcare services in the region. The solution will handle 200,000 examinations per year.
Under the terms of the agreement, the IT solution for handling digital pathology images will enable pathologists at the region's four hospitals to review and collaborate around cases in a way that is not possible with microscopes. This will increase efficiency in primary diagnostics, thereby improving cancer care, revealed the company.
According to the company, the digital pathology solution includes digital tools which enable pathologists to make their diagnoses and carry out reporting with higher precision and less time spent per case. It is a complete, vendor-neutral solution for primary diagnostics that includes storage solutions and an advanced review workstation.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis